Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer

Anne Sophie Mehdorn, Timo Gemoll, Hauke Busch, Katharina Kern, Silje Beckinger, Tina Daunke, Christoph Kahlert, Faik G. Uzunoglu, Alexander Hendricks, Florian Buertin, Uwe A. Wittel, Yoshiaki Sunami, Christoph Röcken, Thomas Becker, Susanne Sebens*

*Korrespondierende/r Autor/-in für diese Arbeit


Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies with poor survival rates. Only 20% of the patients are eligible for R0-surgical resection, presenting with early relapses, mainly in the liver. PDAC patients with hepatic metastases have a worse outcome compared to patients with metastases at other sites. Early detection of hepatic spread bears the potential to improve patient outcomes. Thus, this study sought for serum-based perioperative biomarkers allowing discrimination of early (EHMS ≤ 12 months) and late hepatic metastatic spread (LHMS > 12 months). Serum samples from 83 resectable PDAC patients were divided into EHMS and LHMS and analyzed for levels of inflammatory mediators by LEGENDplexTM, which was validated and extended by Olink® analysis. CA19-9 serum levels served as control. Results were correlated with clinicopathological data. While serum CA19-9 levels were comparable, Olink® analysis confirmed distinct differences between both groups. It revealed significantly elevated levels of factors involved in chemotaxis and migration of immune cells, immune activity, and cell growth in serum of LHMS-patients. Overall, Olink® analysis identified a comprehensive biomarker panel in serum of PDAC patients that could provide the basis for predicting LHMS. However, further studies with larger cohorts are required for its clinical translation.

PublikationsstatusVeröffentlicht - 10.2022

Strategische Forschungsbereiche und Zentren

  • Profilbereich: Lübeck Integrated Oncology Network (LION)


Untersuchen Sie die Forschungsthemen von „Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer“. Zusammen bilden sie einen einzigartigen Fingerprint.